Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Safety Study of Avacincaptad Pegol in Geographic Atrophy (Post-GATHER2)
2024-515185-13-00Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2024
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of avacincaptad pegol in geographic atrophy (GA), sponsored by Astellas Pharma. Primary endpoint: Adverse events. Started Oct 2024; status: completed.
02
Drugs
avacincaptad pegol
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on 2024-515185-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515185-13-00.